Dabrafenib: all 106 studies that test it

Page 1 of 2. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerNot yet recruitingNCT07886905Phase 2
• A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerRecruitingNCT07506109Phase 2
• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingNCT07440290Phase 2/3
• Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasRecruitingNCT07110246Phase 2
• Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingNCT07010393Phase 4
• Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2
• MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasRecruitingNCT06712875Phase 1/2
• Clinical Study of Neoadjuvant Targeted Therapy for AmeloblastomaRecruitingNCT06653517Phase 2
• Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingNCT06563999Phase 2
• Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant AmeloblastomaNot yet recruitingNCT06264778Phase 3
• Precision Cancer Therapy in Rare CancersRecruitingNCT06119789Phase 2
• Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene AlterationsRecruitingNCT05876806Phase 2
• A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)RecruitingNCT05182931Phase 2
• The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
• A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingNCT04116541Phase 2
• Melanoma Metastasized to the Brain and SteroidsRecruitingNCT03563729Phase 2
• Dabrafenib and/or Trametinib Rollover StudyRecruitingNCT03340506Phase 4
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid CancerActive, not recruitingNCT04940052Phase 3Results posted
• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentActive, not recruitingNCT04557956Phase 1/2Results posted
• A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLCCompletedNCT04452877Phase 2Results posted
• Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)Active, not recruitingNCT04439292Phase 2Results posted
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaTerminatedNCT04310397Phase 2Results posted
• Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related OutcomesCompletedNCT03551626Phase 3Results posted
• E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)TerminatedNCT03332589Phase 1Results posted
• INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.TerminatedNCT03272464Phase 1Results posted
• Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain MetastasesTerminatedNCT02974803Phase 2Results posted
• Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III MelanomaActive, not recruitingNCT02858921Phase 2Results posted
• Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG TumorsCompletedNCT02684058Phase 2Results posted
• Dabrafenib and Trametinib in Treating Patients With BRAF Mutated AmeloblastomaCompletedNCT02367859Phase 2Results posted
• Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or TrametinibTerminatedNCT02314143Phase 2Results posted
• Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester DiseaseCompletedNCT02281760Phase 2Results posted
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaActive, not recruitingNCT02224781Phase 3Results posted
• A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)CompletedNCT02130466Phase 1/2Results posted
• Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 MutationsCompletedNCT02124772Phase 1/2Results posted
• Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02097225Phase 1Results posted
• Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive MelanomaCompletedNCT02083354Phase 2Results posted
• Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the BrainCompletedNCT02039947Phase 2Results posted
• Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersCompletedNCT02034110Phase 2Results posted
• Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)CompletedNCT01928940Phase 2Results posted
• Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerCompletedNCT01902173Phase 1/2Results posted
• BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)CompletedNCT01750918Phase 1/2Results posted
• Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain MetsTerminatedNCT01721603Phase 2Results posted
• Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By SurgeryTerminatedNCT01701037Phase 2Results posted
• Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K MutationCompletedNCT01682213Phase 2Results posted
• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).CompletedNCT01682083Phase 3Results posted
• A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent SubjectsCompletedNCT01677741Phase 1/2Results posted
• An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF InhibitorCompletedNCT01619774Phase 2Results posted
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous MelanomaCompletedNCT01597908Phase 3Results posted
• Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436CompletedNCT01534897Not applicableResults posted
• A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the BrainCompletedNCT01266967Phase 2Results posted
• A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) MelanomaCompletedNCT01227889Phase 3Results posted
• A Study of GSK2118436 in BRAF Mutant Metastatic MelanomaCompletedNCT01153763Phase 2Results posted
• A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05585320Phase 1/2
• E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic MelanomaTerminatedNCT05388877Phase 1
• "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"WithdrawnNCT05299580Phase 2
• Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
• Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid CancerWithdrawnNCT04739566Phase 2
• Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid CancerActive, not recruitingNCT04675710Phase 2
• JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway MutationsSuspendedNCT04418167Phase 1
• Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid CancerActive, not recruitingNCT04238624Phase 2
• A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF AberrationActive, not recruitingNCT04201457Phase 1/2
• Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy SubjectsCompletedNCT04092725Phase 1
• Pediatric Long-Term Follow-up and Rollover StudyActive, not recruitingNCT03975829Phase 4
• Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid CancerSuspendedNCT03975231Phase 1
• Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaActive, not recruitingNCT03919071Phase 2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 MutationsWithdrawnNCT03794297Phase 2
• Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3
• Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant MelanomaStatus unknownNCT03754179Phase 1/2
• Dabrafenib + Trametinib + PDR001 In Colorectal CancerStatus unknownNCT03668431Phase 2
• A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant MelanomaTerminatedNCT03391050Phase 1/2
• Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic MelanomaCompletedNCT03352947Phase 2
• Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid CancerCompletedNCT03244956Phase 2
• Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2
• A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT03091257Phase 1
• Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced MelanomaStatus unknownNCT03088176Phase 1
• A Clinical Trial of Patients With MelanomaWithdrawnNCT02915666Phase 1
• Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaActive, not recruitingNCT02910700Phase 2
• Pharmacokinetics of Dabrafenib in Subjects With Hepatic ImpairmentTerminatedNCT02873650Phase 1
• BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic MelanomaCompletedNCT02872259Phase 1/2
• Pharmacokinetics of Dabrafenib in Subjects With Renal ImpairmentCompletedNCT02852239Phase 1
• Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLCWithdrawnNCT02672358Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With MelanomaWithdrawnNCT02447939Phase 1
• Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced MelanomaTerminatedNCT02410863Phase 2
• Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or TrametinibWithdrawnNCT02357732Phase 1
• Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationActive, not recruitingNCT02231775Phase 2
• Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV MelanomaTerminatedNCT02200562Phase 1
• Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadActive, not recruitingNCT02196181Phase 2
• Study of Dabrafenib, Trametinib and Metformin for Melanoma PatientsWithdrawnNCT02143050Phase 1/2
• A Phase 1b/2a Study Evaluating AMG 232 in Metastatic MelanomaCompletedNCT02110355Phase 1
• Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and MidazolamCompletedNCT02082665Phase 1
• Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb StudyTerminatedNCT02052193Phase 2
• Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneCompletedNCT02027961Phase 1
• Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive MelanomaCompletedNCT01972347Phase 2
• A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive TumorsCompletedNCT01954043Phase 1
• Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by SurgeryActive, not recruitingNCT01947023Phase 1
• Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01940809Phase 1
• Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver DysfunctionTerminatedNCT01907802Phase 1

← Dabrafenib overview